

## Regimen Reference Order – MULTI – larotrectinib

ARIA: MULTI - [larotrectinib]

ARIA Support: PEDS - [larotrectinib]

**Planned Course:** Orally twice daily until disease progression or unacceptable toxicity  
(1 cycle = 28 days)

**Indication for Use:** Neurotrophic Tyrosine Receptor Kinase (NTRK) positive tumors

**Proceed with treatment if:**

**ANC equal to or greater than  $1 \times 10^9/L$  AND Platelets equal to or greater than  $75 \times 10^9/L$**

❖ **Contact Physician if parameters not met**

### SEQUENCE OF MEDICATION ADMINISTRATION

#### Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

#### Treatment Regimen – MULTI – larotrectinib

Drug	Dose	CCMB Administration Guideline
larotrectinib	<u>Adults:</u> 100 mg  <u>Pediatrics:</u> 100 mg/m <sup>2</sup> (maximum dose 100 mg; for volume below 1 mL round to nearest 0.1 mL <b>OR</b> for volume above 1 mL round to nearest 0.5 mL)	Orally twice daily with or without food Swallow whole <b>(Self-administered at home)</b>
<b>larotrectinib (VITRAKVI®) available dosage strengths: 25 mg and 100 mg capsules; and 20 mg/mL oral solution</b> <b>Classification: Cytotoxic, Hazardous</b>		

### REQUIRED MONITORING

Cycle 1

Day 1

- CBC, serum creatinine, urea, electrolytes, liver enzymes and total bilirubin as per Physician Orders

Day 15

- Liver enzymes and total bilirubin

Cycle 2 and Onwards

Day 1

- CBC, serum creatinine, urea, liver enzymes, total bilirubin, electrolytes as per Physician Orders

### Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
None required		

### INSTRUCTIONS FOR PATIENT

- Patient should notify clinic if they experience neurologic symptoms (e.g. dizziness, mental status changes or gait disturbances)
- larotrectinib has potential for drug-drug interactions. Patients should notify clinic prior to starting any new medication
- Avoid grapefruit or grapefruit juice, Seville oranges (i.e. orange marmalade) and starfruit
- Reinforce applicable safe handling precautions of medications, blood and body fluids while on larotrectinib

### ADDITIONAL INFORMATION

- larotrectinib can cause neurological symptoms and cognitive impairment
- larotrectinib can cause hepatotoxicity
- Support protocol for suspension is available under **larotrectinib** in the “Pediatrics” folder. Manual calculation and manual entry of the dose is required
- larotrectinib will be dispensed by CCMB Pharmacy